TY  - JOUR
AU  - Rittmeyer, Achim
AU  - Barlesi, Fabrice
AU  - Waterkamp, Daniel
AU  - Park, Keunchil
AU  - Ciardiello, Fortunato
AU  - von-Pawel, Joachim
AU  - Gadgeel, Shirish M
AU  - Hida, Toyoaki
AU  - Kowalski, Dariusz M
AU  - Dols, Manuel Cobo
AU  - Cortinovis, Diego L
AU  - Leach, Joseph
AU  - Polikoff, Jonathan
AU  - Barrios, Carlos
AU  - Kabbinavar, Fairooz
AU  - Frontera, Osvaldo Aren
AU  - De-Marinis, Filippo
AU  - Turna, Hande
AU  - Lee, Jong-Seok
AU  - Ballinger, Marcus
AU  - Kowanetz, Marcin
AU  - He, Pei
AU  - Chen, Daniel S
AU  - Sandler, Alan
AU  - Gandara, David R
PY  - 2017
DO  - 10.1016/S0140-6736(16)32517-X
UR  - http://hdl.handle.net/10668/10684
T2  - Lancet (London, England)
AB  - Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus...
LA  - en
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Disease-Free Survival
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - Docetaxel
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Infusions, Intravenous
KW  - Kaplan-Meier Estimate
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Taxoids
KW  - Treatment Outcome
TI  - Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
TY  - research article
VL  - 389
ER  -